

# BRAIN TUMOR ANALYSIS REPORT

## AI-Powered Segmentation and Clinical Assessment

### Patient Information

Field	Value
Report Date	2025-09-18T10:09:50.726017
Case ID	case_880b6556-bacf-419b-b6a1-a8a059cba2b2
Patient Id	321
Patient Age	22
Patient Gender	male

# AI-GENERATED CLINICAL REPORT

## EXECUTIVE SUMMARY

This case demonstrates a large right-sided central brain tumor with heterogeneous tissue composition, including a small necrotic component and significant peritumoral edema. The enhancing tumor volume represents approximately 20.5% of the total tumor volume, consistent with a moderately enhancing lesion. The presence of edema and focal necrosis, combined with the tumor's size and location, warrants urgent multidisciplinary evaluation and consideration of histopathological confirmation.

## TUMOR MORPHOLOGY AND LOCATION

- Location: Right hemisphere, central region
- Size Classification: Very large ( $>15\text{ cm}^3$ )
- Maximum Diameter: 62.0 mm
- Anatomical Considerations: The central location in the right hemisphere may involve critical structures such as the corpus callosum, internal capsule, or adjacent white matter. This location can influence motor and cognitive function and may pose challenges for surgical resection and radiation planning.

## QUANTITATIVE ANALYSIS

- Total Tumor Volume: 52.92  $\text{cm}^3$
- Tumor Core Volume: 11.12  $\text{cm}^3$
- Enhancing Component: 10.86  $\text{cm}^3$  (20.5%)
- Necrotic Component: 0.26  $\text{cm}^3$  (0.5%)
- Edematous Component: 41.80  $\text{cm}^3$  (79.0%)

## ENHANCEMENT CHARACTERISTICS

- Enhancement Pattern: Moderate (10–30%)
- Enhancement Intensity: Mean 520.73, Maximum 1146.00
- Clinical Significance: Moderate enhancement is consistent with high-grade glioma or other aggressive neoplasms. The presence of enhancement without significant rim enhancement may suggest a more diffuse infiltrative pattern or early treatment response.

## TISSUE COMPOSITION ANALYSIS

Tissue Component	Present/Absent	Clinical Interpretation
Enhancing Tissue	Present	Indicates active tumor proliferation and blood-brain barrier disruption.
Necrotic Core	Present	Minimal necrosis (0.5%) suggests relatively well-vascularized tumor with low central ischemia.
Peritumoral Edema	Present	Extensive edema (79%) is associated with significant mass effect and may indicate aggressive tumor behavior.

## CLINICAL ASSESSMENT

- Tumor Grade Indicators: Moderate enhancement, minimal necrosis, and extensive edema are consistent with high-grade glioma (e.g., glioblastoma or anaplastic astrocytoma).
- Differential Diagnosis: Likely diagnosis includes glioblastoma multiforme (GBM), anaplastic astrocytoma, or oligodendrogloma with secondary changes. Other considerations include metastatic disease or lymphoma if clinical history supports.
- Prognosis Indicators: Extensive edema and large tumor volume are associated with poorer prognosis. The presence of minimal necrosis may suggest a more indolent histology, but further histopathological confirmation is essential.

## RECOMMENDATIONS

1. Immediate Actions: Urgent neurosurgical consultation for potential biopsy or resection planning.
2. Additional Imaging: Consider perfusion MRI and MR spectroscopy for further characterization.
3. Multidisciplinary Review: Involvement of neuro-oncology, radiation oncology, and neuropathology for comprehensive care.
4. Follow-up Protocol: MRI with contrast at 3–6 months post-intervention to assess treatment response.
5. Treatment Considerations: Consider surgical resection, followed by adjuvant radiation and chemotherapy based on histopathology results.

## TECHNICAL NOTES

- Image Quality: Adequate for diagnostic interpretation
- Segmentation Confidence: High automated detection accuracy
- Limitations: Standard limitations of MRI-based analysis include potential underestimation of infiltrative components and variability in enhancement patterns. Functional imaging modalities may be needed for further differentiation.

Report Generated: September 18, 2025 at 10:09 AM

System: AI-Assisted Brain Tumor Analysis Platform

Case ID: case\_880b6556-bacf-419b-b6a1-a8a059cba2b2

Patient ID: 321


Age: 22

Gender: Male

# SEGMENTATION VISUALIZATIONS


## FLAIR Segmentation Overlay

FLAIR with Segmentation Overlay



## T1CE Segmentation Overlay


### T1CE with Segmentation Overlay



■ Necrotic Core ■ Peritumoral Edema ■ Enhancing Tumor

### T2 Segmentation Overlay

#### T2 with Segmentation Overlay



■ Necrotic Core ■ Peritumoral Edema ■ Enhancing Tumor

### 3D Volume Analysis

### 3D Tumor Segmentation Views


Sagittal View




Coronal View



Axial View




Tumor Component Volumes (voxels)




# QUANTITATIVE ANALYSIS


Tumor Component Distribution




Component Volume Comparison



Tissue Composition Percentages



Tumor Size Classification  
(Current: 52.92 cm<sup>3</sup>)



### Clinical Summary Table

Parameter	Value	Clinical Significance
Total Volume	52.92 cm <sup>3</sup>	very_large (>15 cm <sup>3</sup> )
Maximum Diameter	62.0 mm	Surgical planning reference
Enhancement	20.5%	moderate (10-30%)
Necrosis	0.5%	minimal (<10%)
Location	right central	Functional considerations
Enhancement Present	yes	Blood-brain barrier disruption
Necrosis Present	yes	Tissue viability indicator
Edema Present	yes	Peritumoral involvement

## **IMPORTANT DISCLAIMERS**

- This report is generated using artificial intelligence algorithms for automated brain tumor segmentation and analysis.
- The AI model used for report generation is designed to assist healthcare professionals but does not replace clinical judgment.
- All quantitative measurements and assessments should be validated by qualified radiologists and medical professionals.
- Treatment decisions should not be based solely on this automated analysis.
- This system is intended for research and educational purposes and to support clinical decision-making.
- Report generated on September 18, 2025 at 10:09 AM using microsoft/DialoGPT-medium.